Pharma

Actavis to refocus pain medication sales in QRxPharma licensing deal

Generic pharmaceutical manufacturer Actavis Group’s U.S. subsidiary has agreed to partner with clinical stage specialty pharmaceutical company QRxPharma in a licensing deal to commercialize acute pain medication MoxDuo IR in the United States, in a move that will reshape the Morristown, New Jersey company’s analgesic sales force for branded products. Under the terms of the […]

Generic pharmaceutical manufacturer Actavis Group’s U.S. subsidiary has agreed to partner with clinical stage specialty pharmaceutical company QRxPharma in a licensing deal to commercialize acute pain medication MoxDuo IR in the United States, in a move that will reshape the Morristown, New Jersey company’s analgesic sales force for branded products.

Under the terms of the agreement in the binding letter of intent, Actavis would get exclusive rights to launch and market MoxDuo IR, a patented fixed-dose combination of morphine and oxycodone, according to a press statement.

The company is set to launch the drug in the third quarter of 2012.

MoxDuo IR has been clinically shown to significantly reduce total opioid dose and side effects, according to QRxPharma’s website

Actavis plans to make MoxDuo IR its flagship product. It will “significantly expand” its analgesic sales force for branded products with MoxDuo IR as a primary focus. The company has produced Kadian for 15 years and marketed it since 2008.